Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

REGENXBIO Inc.

RGNX · Nasdaq · CIK 0001590877 · Healthcare · Biotechnology

INSIDER SIGNAL

37.9 / 100

1 buyers · 2 purchase transaction lines · $949.5K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionLow
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+6.0 / 25
Role+20.0 / 20
Recency+4.2 / 10
Conviction+0.7 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Buying conviction is reduced by concurrent selling
  • ✓ Role scores high · most senior buyer: Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
PAKOLA STEVEChief Medical Officer
▼▼○▼○▼○
Ciongoli Gregory AustinDirector
○●●
Simpson CurranChief Executive Officer
○○
Malzahn CraigChief Technology Officer
○
Chan MitchellChief Financial Officer
○
Christmas Patrick J.Chief Strategy & Legal Officer
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 9 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Ciongoli Gregory Austin · $949.5K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-08-26–2026-08-27

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

37.9 / 100

Latest recorded score

↓ -0.2 ptsversus the previous recorded snapshot
  1. 38.5
  2. 38.3
  3. 38.2
  4. 38.1
  5. 37.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

2Purchases
5Sales
32Other Form 4 lines
31SEC filings · 365 days
BUYING2 qualifying P line(s) · 180 days
SELLING4 sale line(s) · context only
OTHER18 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-5.7%
3M
-36.7%
6M
-8.3%
12M
-34.0%

Volatility & liquidity

Volatility
89.3%
Beta
—
Avg daily value
USD 11.9M

Valuation

Market cap
USD 532.7M
P/E
—

Fundamentals

Profit margin
-113.8%
ROE
-188.7%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
9,608,992
Previous report
7,927,603
Avg daily volume
1,603,635
Days to cover
6.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-27Ciongoli Gregory AustinPurchase (P)Common Stock53,407USD 9.36USD 499,890SEC filing ↗
2026-08-26Ciongoli Gregory AustinPurchase (P)Common Stock49,196USD 9.14USD 449,651SEC filing ↗

Form 4 evidence

39 transaction lines in the latest 365-day window; 312 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Malzahn CraigTax withholding (F)Common Stock234USD 9.32USD 2,181SEC filing ↗
2026-09-01Chan MitchellTax withholding (F)Common Stock4,902USD 9.32USD 45,687SEC filing ↗
2026-08-27Ciongoli Gregory AustinPurchase (P)Common Stock53,407USD 9.36USD 499,890SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-01Malzahn CraigTax withholding (F)Common Stock234USD 9.32USD 2,181SEC filing ↗
2026-09-01Chan MitchellTax withholding (F)Common Stock4,902USD 9.32USD 45,687SEC filing ↗
2026-08-27Ciongoli Gregory AustinPurchase (P)Common Stock53,407USD 9.36USD 499,890SEC filing ↗
2026-08-26Ciongoli Gregory AustinPurchase (P)Common Stock49,196USD 9.14USD 449,651SEC filing ↗
2026-08-25Ciongoli Gregory AustinAward / grant (A)Common Stock15,432USD 0.00USD 0SEC filing ↗
2026-08-01PAKOLA STEVETax withholding (F)Common Stock7,468USD 9.69USD 72,365SEC filing ↗
2026-08-01Christmas Patrick J.Tax withholding (F)Common Stock4,699USD 9.69USD 45,533SEC filing ↗
2026-07-02PAKOLA STEVESale (S)Common Stock2,161USD 13.64USD 29,476SEC filing ↗
2026-07-02PAKOLA STEVEOption exercise / conversion (M)Common Stock2,161USD 7.86USD 16,985SEC filing ↗
2026-07-01Simpson CurranTax withholding (F)Common Stock6,818USD 13.09USD 89,248SEC filing ↗
2026-07-01PAKOLA STEVESale (S)Common Stock36,725USD 12.86USD 472,284SEC filing ↗
2026-07-01PAKOLA STEVEOption exercise / conversion (M)Common Stock36,725USD 7.86USD 288,658SEC filing ↗
2026-06-30Simpson CurranAward / grant (A)Common Stock1,453USD 10.18USD 14,792SEC filing ↗
2026-06-29PAKOLA STEVESale (S)Common Stock19,608USD 11.04USD 216,472SEC filing ↗
2026-05-29Zachary JenniferAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29Tasse DanielAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29STUMP DAVID CAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29Mills Kenneth T.Award / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29MIGAUSKY GEORGE VAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29KARABELAS ARGERIS NAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29Glucksmann AlexandraAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29Fox Allan M.Award / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-29Bennett JeanAward / grant (A)Common Stock9,807USD 0.00USD 0SEC filing ↗
2026-05-11PAKOLA STEVESale (S)Common Stock15,309USD 11.02USD 168,705SEC filing ↗
2026-03-10PAKOLA STEVESale (S)Common Stock5,124USD 10.35USD 53,033SEC filing ↗
2026-02-01PAKOLA STEVETax withholding (F)Common Stock5,267USD 11.16USD 58,780SEC filing ↗
2026-02-01Christmas Patrick J.Tax withholding (F)Common Stock4,700USD 11.16USD 52,452SEC filing ↗
2026-01-27Mills Kenneth T.Option exercise / conversion (M)Common Stock225,000USD 13.09USD 2,945,250SEC filing ↗
2026-01-27Mills Kenneth T.Tax withholding (F)Common Stock221,753USD 13.41USD 2,973,708SEC filing ↗
2026-01-06Simpson CurranAward / grant (A)Common Stock144,864USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerRGNX
CIK0001590877
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history312 transaction lines from 2020-01-08 to 2026-09-01
2 P purchase lines · 103 S sale lines · 207 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.